The IDEXX Cystatin B Test can help
veterinarians detect kidney injury before changes in kidney
function, promoting better patient outcomes
WESTBROOK, Maine, June 15,
2023 /PRNewswire/ -- IDEXX Laboratories, Inc.
(NASDAQ: IDXX), a global leader in pet healthcare innovation, today
announced the launch of the first veterinary diagnostic test for
detecting kidney injury in cats and dogs. According to a recent
IDEXX survey, as many as one-third of kidney cases seen by
veterinarians are related to kidney injury, and a diagnosis can be
challenging due to subtle or nonspecific
signs.1 The IDEXX Cystatin B Test will be included
in test panels assessing renal health, uncovering new clinical
insights for an estimated two million patient visits annually.
These tests will be run at IDEXX Reference Laboratories starting
later this year in the U.S. and Canada, with plans to introduce the test in
Europe in 2024.
The kidneys are vital to the overall health of a patient,
regulating blood pressure, electrolyte balance, and red blood cell
production, and removing toxins. IDEXX SDMA testing provides
veterinarians with unmatched insights into kidney function, and the
IDEXX Cystatin B Test will enhance their view into kidney health by
detecting injury and providing additional clarity when a change in
kidney function may not be apparent. Together, the IDEXX Cystatin B
and IDEXX SDMA® tests offer a comprehensive view of the
kidneys by uncovering structural injury and impaired kidney
function.
"With the addition of the IDEXX Cystatin B Test, we are pleased
to offer the industry's first biomarker for kidney injury," said
Jay Mazelsky, IDEXX President and
Chief Executive Officer. "The IDEXX portfolio of tests and
technologies enables veterinarians to intervene earlier, advance
treatment, and now detect kidney injury, resulting in better
outcomes throughout the lives of their patients."
The IDEXX expanded renal testing portfolio now includes:
- IDEXX Cystatin B Test, detecting kidney injury with or
without changes in kidney function, providing valuable insights in
cases such as early toxin exposure.
- IDEXX SDMA® Test and creatinine, helping to
establish a baseline for kidney function for monitoring and early
kidney disease detection.
- IDEXX FGF-23 Test, allowing for more confident
recommendations of targeted therapy for cats diagnosed with chronic
kidney disease (CKD) by monitoring phosphorous overload.
- Urine testing, providing a deeper understanding of total
kidney health by examining the physical and chemical properties of
urine.
For more information on the IDEXX Cystatin B Test and IDEXX
kidney health solutions, please visit IDEXX Cystatin B.
A joint statement from three founding members of the American
College of Veterinary Nephrology and Urology accentuates the value
this novel biomarker holds in the industry and aligns with a recent
statement from the International Renal Interest
Society (IRIS):
"The advent of diagnostic biomarkers capable to detect the
presence of acute kidney injury as well as active and ongoing
kidney injury in advance of or in the absence of changes in
conventional markers of kidney function forecast an important
advance in the evaluation of acute and chronic kidney disease in
dogs. The development and validation of Cystatin-B as an active
kidney injury biomarker in dogs that will be readily available to
veterinarians has the potential to reshape the future diagnostic
and therapeutic directions of kidney disease. As nephrologists, we
anxiously await this new era of early disease discovery and
management."
Dr, Gilad Segev, DVM, Dip.
ECVIM-CA (Internal Medicine)
American College of Veterinary Nephrology and Urology, Founding
Member
Associate Professor of Veterinary Medicine
Head, Small Animal Internal Medicine
Koret School of Veterinary
Medicine
The Hebrew University of Jerusalem
Dr. Shelly Vaden, DVM, PhD,
DACVIM (SAIM)
American College of Veterinary Nephrology and Urology, Founding
Member
Professor Internal Medicine (Nephrology and Urology)
Medical Director, Extracorporeal Therapies
Chief of Staff, Small Animal
North Carolina State University, College of
Veterinary Medicine
Larry D. Cowgill, DVM, PhD, Dipl.
ACVIM (SAIM)
American College of Veterinary Nephrology and Urology, Founding
Member
Professor, Department of Medicine & Epidemiology
2108 Tupper Hall
School of Veterinary Medicine
University of California-Davis
About IDEXX
IDEXX is a global leader in pet healthcare
innovation. Our diagnostic and software products and services
create clarity in the complex, constantly evolving world of
veterinary medicine. We support longer, fuller lives for pets by
delivering insights and solutions that help the veterinary
community around the world make confident decisions—to advance
medical care, improve efficiency, and build thriving practices. Our
innovations also help ensure the safety of milk and water across
the world and maintain the health and well-being of people and
livestock. IDEXX Laboratories, Inc. is a member of the S&P
500® Index. Headquartered in Maine, IDEXX employs nearly 11,000 people and
offers solutions and products to customers in more than 175
countries. For more information about IDEXX, visit: idexx.com.
For media inquiries, please get in touch
at media@idexx.com.
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
the use of words such as "expects," "may," "anticipates,"
"intends," "would," "will," "plans," "believes," "estimates,"
"should," "project," and similar words and expressions. These
forward-looking statements are intended to provide our current
expectation or forecasts of future events; are based on current
estimates, projections, beliefs, and assumptions; and are not
guarantees of future performance. Actual events or results may
differ materially from those described in the forward-looking
statements. These statements are subject to risks, uncertainties,
assumptions, and other important factors. Readers are cautioned not
to put undue reliance on such forward-looking statements because
actual results may vary materially from those expressed or implied.
The reports filed by IDEXX pursuant to United States securities laws contain
discussions of some of these risks and uncertainties. IDEXX assumes
no obligation to, and expressly disclaims any obligation to, update
or revise any forward-looking statements, whether as a result of
new information, future events, or otherwise. Readers are advised
to review IDEXX's filings with the United States Securities and
Exchange Commission (which are available from the SEC's EDGAR
database at sec.gov and via IDEXX's website at idexx.com).
References
- Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: Data from IDEXX global
survey conducted August 2021–September 2021.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/idexx-announces-novel-diagnostic-test-for-kidney-injury-expanding-the-veterinary-industrys-most-comprehensive-renal-testing-portfolio-301851414.html
SOURCE Idexx Laboratories, Inc.